Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Implantica AGFRA:8IM1 -4.46%34 Debt-to-EBITDA is 0.00 as of . 20. GuruFocus rates FRA:8IM1 with a GF Score™ of 34/100. Among 475 Medical Devices & Instruments companies, Implantica AG ranks worse than 210526.11% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Implantica AG's Debt-to-EBITDA or its related term are showing as below:
FRA:8IM1's Debt-to-EBITDA is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.63 * Ranked among companies with meaningful Debt-to-EBITDA only.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Implantica AG Debt-to-EBITDA Related Terms
Implantica AG Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Implantica AG's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Implantica AG Debt-to-EBITDA Chart
Implantica AG Annual Data
Trend
Debt-to-EBITDA
Implantica AG Semi-Annual Data
Debt-to-EBITDA
FRA:8IM1 vs : Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Implantica AG's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Implantica AG Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Implantica AG's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Implantica AG's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is one times the quarterly (. 20) EBITDA data.
Implantica AG (FRA:8IM1) has a Debt-to-EBITDA of 0.00 as of . 20. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Implantica AG. According to the industry distribution chart, Implantica AG ranks #999999 out of 475 companies in the Medical Devices & Instruments industry.
Is Implantica AG's Debt-to-EBITDA too high?
Implantica AG's current Debt-to-EBITDA is 0.00. Based on the distribution chart, Implantica AG ranks #999999 out of 475 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Implantica AG has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Implantica AG's Debt-to-EBITDA compare to ?
According to the Medical Devices & Instruments industry distribution chart, Implantica AG ranks #999999 out of 475 companies for Debt-to-EBITDA. This places Implantica AG in the lower half of its industry. The industry median Debt-to-EBITDA is 1.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.63, based on 475 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Implantica AG. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Implantica AG's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Implantica AG stock overvalued right now?
Implantica AG (FRA:8IM1) has a current Debt-to-EBITDA of 0.00. The current Debt-to-EBITDA is 0.00. Implantica AG's overall GF Score™ is 34/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Implantica AG (FRA:8IM1), the current Debt-to-EBITDA is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Implantica AG is a medtech group providing effective care for serious health conditions and improving patients' quality of life by bringing technology into the body. The therapies Implantica develops are based on implants that are medical devices inserted into the patient's body and are intended to remain in place permanently or semi-permanently, using electrical power provided by a battery. The company has developed a broad, patent-protected product pipeline based partly on its two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body, and communicate with the caregiver at a distance, and a wireless energising platform designed to power remote-controlled implants wirelessly through intact skin.
34GF Score
Get the complete analysis for FRA:8IM1
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8IM1 has been successfully added to your 
